[177Lu]Lu-labeled anti-claudin-18.2 antibody demonstrated radioimmunotherapy potential in gastric cancer mouse xenograft models
ConclusionIn preclinical studies, [177Lu]Lu-TST001 demonstrated significant antitumor efficacy with acceptable toxicity. It exhibits strong potential for clinical translation, providing a new promising treatment option for CLDN18.2-overexpressing tumors, including GC.
Source: European Journal of Nuclear Medicine and Molecular Imaging - Category: Nuclear Medicine Source Type: research
More News: Cancer | Cancer & Oncology | Cardiology | Gastric (Stomach) Cancer | Gastroenterology | Heart | Liver | Nuclear Medicine | Study | Toxicology | Urology & Nephrology